Loading...

VNDA VANDA PHARMACEUTICALS INC Company Mergers 8-K Filing

VND

VND

VANDA PHARMACEUTICALS INC

(VNDA)

2024 8-K

Show Summary

Show Summary

Financial Statements

FDA Application Update

Executive Compensation

Earnings Results

New Drug Application

Earnings Announcement

Acquisition Proposal

Bylaw Amendments

Tradipitant Update

Amendment to Rights Agreement

Rejection of Acquisition Pr...

Acquisition Proposal

Indication of Interest

Rejection of Acquisition Pr...

Management Changes

Annual Meeting of Stockholders

Acquisition Proposal

Dividend Distribution

FDA Response Letter

Compensation Committee Awar...

Amendment to Form 8-K/A

FDA Update on Insomnia Trea...

Bylaws Amendment

Acquisition of PONVORY Rights

Denial of Rehearing

Annual Meeting Voting Results

Appointment of Director

Regulation FD Disclosure

Compensation Committee Awar...

External Links:

Vanda Pharmaceuticals Inc. filed an amendment to provide financial statements and information related to the acquisition of the U.S. and Canadian rights for PONVORY from Actelion Pharmaceuticals Ltd.

AI Assistant

VANDA PHARMACEUTICALS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.